Genistein as a Therapeutic Agent in the Prodromal Phase of Alzheimer's Disease: Systematic Review
Genistein has been shown to improve cognitive function and reduce beta-amyloid deposition in patients with prodromal Alzheimer's disease. However, small sample sizes and variability in dosages limit the generalizability of these findings. Future trials with larger cohorts and standardized protocols are needed to validate these results.
Authors
- Kevin Gustavo dos Santos Silva (ORCID: https://orcid.org/0000-0001-9286-5244)
- Carlos Rocha Oliveira (ORCID: https://orcid.org/0000-0002-2662-8379)
- Grazielle Larissa Fonte Alves
- Vinícius Ferreira Souza
Institutions
- Anhembi Morumbi University (BR)
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103969
- Primary Topic
- Phytoestrogen effects and research
- Type
- article
- Field-Weighted Citation Impact
- 0.00